LBI-0222
THERAPEUTIC AREA
BLOOD CANCER
Indications
Multiple Myeloma, Leukemia
REGULATORY PATHWAY
New NDA
TARGET INDICATION
New chemical entity (NCE) kinase inhibitor analogue
CURRENT DEVELOPMENT STATUS
Molecules have been designed. Development is paused until funding and staff are secured and solid tumor program advances to human trials
NEXT DEVELOPMENT PHASE
Utilize Luminus nano-platform to synthesize multiple drug molecules and rational drug combinations, screen and select lead candidate
TIME TO HUMAN BENEFIT
Human trials beginning as soon as 2 years from funding and staffing
IMMEDIATE FUNDING REQUIRED?
Yes, please inquire